Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTOR Citius Oncology	$1.63 +1.2%	$2.46	$0.55 ▼ $6.19	$126.18M	3	521,489 shs	78,243 shs
PVLA Palvella Therapeutics	$51.31 +1.7%	$32.41	$11.17 ▼ $52.87	$557.85M	-0.01	153,449 shs	132,069 shs
SAGE Sage Therapeutics	$8.68	$8.90	$4.62 ▼ $11.44	$543.54M	0.26	3.63 million shs	N/A
SNDL SNDL	$2.24 +1.4%	$1.55	$1.15 ▼ $2.40	$580.73M	3.57	4.61 million shs	2.37 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTOR Citius Oncology	+1.24%	-5.23%	-1.21%	+79.12%	-15.54%
PVLA Palvella Therapeutics	+1.72%	+11.30%	+42.53%	+116.32%	+5,130,999,900.00%
SAGE Sage Therapeutics	0.00%	0.00%	-0.80%	+32.92%	+0.35%
SNDL SNDL	+1.36%	+6.16%	+36.59%	+73.64%	+6.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTOR Citius Oncology	1.4147 of 5 stars	3.0	0.0	0.0	2.0	1.7	0.0
PVLA Palvella Therapeutics	2.8703 of 5 stars	3.5	0.0	0.0	2.9	2.5	0.6
SAGE Sage Therapeutics	3.4087 of 5 stars	2.0	5.0	4.1	0.6	1.7	0.6
SNDL SNDL	1.8376 of 5 stars	2.0	3.0	0.0	2.5	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTOR Citius Oncology	2.00	Hold	$3.00	84.05% Upside
PVLA Palvella Therapeutics	3.09	Buy	$58.50	14.01% Upside
SAGE Sage Therapeutics	1.93	Reduce	$7.85	-9.56% Downside
SNDL SNDL	0.00	N/A	$4.00	78.57% Upside

Current Analyst Ratings Breakdown

Latest CTOR, PVLA, SAGE, and SNDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $66.00
8/15/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $75.00
8/15/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $60.00
8/5/2025	PVLA Palvella Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$54.00
8/4/2025	PVLA Palvella Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$90.00
7/21/2025	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$56.00
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.41 per share	N/A
PVLA Palvella Therapeutics	$42.81M	13.26	N/A	N/A	$4.32 per share	11.88
SAGE Sage Therapeutics	$41.24M	13.18	N/A	N/A	$5.89 per share	1.47
SNDL SNDL	$671.81M	0.88	N/A	N/A	$2.99 per share	0.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTOR Citius Oncology	N/A	N/A	0.00	∞	N/A	N/A	-51.93%	-22.17%	N/A
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-62.30%	-43.34%	N/A
SAGE Sage Therapeutics	-$400.67M	-$4.89	N/A	N/A	N/A	-427.78%	-67.10%	-58.42%	11/4/2025 (Estimated)
SNDL SNDL	-$69.18M	-$0.27	N/A	N/A	N/A	-10.38%	-8.58%	-7.23%	11/4/2025 (Estimated)

Latest CTOR, PVLA, SAGE, and SNDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.78	-$0.86	-$0.08	-$0.86	N/A	N/A
7/31/2025	Q2 2025	SNDL SNDL	-$0.04	$0.01	+$0.05	$0.01	$231.50 million	$179.78 million
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	-$0.79	+$0.17	-$0.79	$16.69 million	$31.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTOR Citius Oncology	0.12	0.35	0.02
PVLA Palvella Therapeutics	N/A	7.67	8.84
SAGE Sage Therapeutics	N/A	9.16	9.13
SNDL SNDL	0.11	5.03	3.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTOR Citius Oncology	70.52%
PVLA Palvella Therapeutics	40.11%
SAGE Sage Therapeutics	99.22%
SNDL SNDL	N/A

Insider Ownership

Company	Insider Ownership
CTOR Citius Oncology	4.57%
PVLA Palvella Therapeutics	20.50%
SAGE Sage Therapeutics	5.50%
SNDL SNDL	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTOR Citius Oncology	N/A	78.37 million	74.79 million	N/A
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
SNDL SNDL	2,516	262.78 million	N/A	Optionable

CTOR, PVLA, SAGE, and SNDL Headlines

Recent News About These Companies

Despite Fast-paced Momentum, SNDL INC (SNDL) Is Still a Bargain Stock

August 21 at 9:50 AM | zacks.com

SNDL (NASDAQ:SNDL) Trading 5.2% Higher - What's Next?

August 20 at 1:51 PM | marketbeat.com

Form 13G SNDL Inc. For: 14 August

August 14, 2025 | investing.com

SNDL (NASDAQ:SNDL) Sees Strong Trading Volume - Here's What Happened

August 13, 2025 | marketbeat.com

Top Canadian Marijuana Stocks If Federal Reform Passes In The USA

August 13, 2025 | marijuanastocks.comM

Investors Buy Large Volume of SNDL Call Options (NASDAQ:SNDL)

August 13, 2025 | marketbeat.com

Traders Purchase Large Volume of Call Options on SNDL (NASDAQ:SNDL)

August 13, 2025 | americanbankingnews.com

Explainer-How US Marijuana Reclassification Could Help Cannabis Companies

August 12, 2025 | usnews.com

SNDL (NASDAQ:SNDL) Shares Gap Up - Here's What Happened

August 12, 2025 | marketbeat.com

SNDL INC (SNDL) Is Attractively Priced Despite Fast-paced Momentum

August 5, 2025 | zacks.com

Atb Cap Markets Forecasts SNDL's Q4 Earnings (NASDAQ:SNDL)

August 4, 2025 | marketbeat.com

SNDL (NASDAQ:SNDL) Issues Earnings Results, Beats Expectations By $0.05 EPS

August 3, 2025 | marketbeat.com

SNDL Inc. Earnings Call: Positive Milestones Amid Challenges

August 2, 2025 | msn.com

SNDL Inc. (SNDL) Expands North American Reach with $32.2M Cannabis Retail Acquisition

August 2, 2025 | finance.yahoo.com

SNDL Inc. (NASDAQ:SNDL) Q2 2025 Earnings Call Transcript

August 1, 2025 | msn.com

SNDL Rallies 20% On Strong Q2 2025 Financial Performance

August 1, 2025 | seekingalpha.com

SNDL Inc.: SNDL Announces 2025 Annual and Special Meeting Results

August 1, 2025 | finanznachrichten.de

SNDL Inc (SNDL) Q2 2025 Earnings Call Highlights: Record Profitability and Strategic Growth ...

August 1, 2025 | finance.yahoo.com

SNDL Announces Successful Outcomes of 2025 Annual Meeting

August 1, 2025 | msn.com

SNDL stock jumps as income turns positive for the first time

August 1, 2025 | msn.com

SNDL Inc. (SNDL) Q2 2025 Earnings Call Transcript

July 31, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CTOR, PVLA, SAGE, and SNDL Company Descriptions

Citius Oncology NASDAQ:CTOR

$1.63 +0.02 (+1.24%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$1.68 +0.06 (+3.37%)

As of 08/21/2025 06:14 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Palvella Therapeutics NASDAQ:PVLA

$51.31 +0.87 (+1.72%)

As of 08/21/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Sage Therapeutics NASDAQ:SAGE

$8.68 0.00 (0.00%)

As of 07/31/2025

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SNDL NASDAQ:SNDL

$2.24 +0.03 (+1.36%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$2.22 -0.02 (-0.67%)

As of 08/21/2025 07:52 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time